Prelude Therapeutics Incorporated

NASDAQ (USD): Prelude Therapeutics Incorporated (PRLD)

Last Price

1.03

Today's Change

0.00 (0.00%)

Day's Change

0.00 - 0.00

Trading Volume

0

Overview

Market Cap

56 Million

Shares Outstanding

55 Million

Avg Volume

497,470

Avg Price (50 Days)

1.09

Avg Price (200 Days)

3.26

PE Ratio

-0.58

EPS

-1.77

Earnings Announcement

13-Feb-2025

Previous Close

1.02

Open

1.02

Day's Range

1.01 - 1.05

Year Range

0.797 - 6.8

Trading Volume

83,207

Price Change Highlight

1 Day Change

0.98%

5 Day Change

-8.85%

1 Month Change

14.99%

3 Month Change

-46.91%

6 Month Change

-83.41%

Ytd Change

-17.60%

1 Year Change

-70.32%

3 Year Change

-88.37%

5 Year Change

-96.07%

10 Year Change

-96.07%

Max Change

-96.07%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment